The legal department at Google DeepMind uses AI to quickly locate and retrieve information, significantly saving time and improving efficiency. (Source: Image by RR)

AI Helps Google and Bayer Slash Time on Rote Tasks, Keeping Human Experts in Charge

Since AI’s rise, employees have debated whether it will replace jobs or enhance efficiency. Google DeepMind is utilizing its Gemini AI model to handle legal information requests, anticipating it will manage 40% to 50% of these tasks, according to Terra Terwilliger, the director of strategic initiatives at Google DeepMind. The AI primarily assists with retrieving crucial data, saving significant time for the legal team. Similarly, Bayer’s global pharmaceuticals division leverages AI to handle 70% to 80% of the regulatory paperwork required for drug research and development, streamlining processes and allowing employees to focus on more valuable tasks.

Both Google DeepMind and Bayer exemplify how AI is transforming organizational efficiency by automating routine tasks, freeing up skilled employees to engage in higher-value work. As noted in a story in finance.yahoo.com, Bayer’s COO, Sebastian Guth, referred to these improvements as “workflow efficiencies” and emphasized the potential for AI to alleviate the burden of paperwork while allowing experts to focus on innovation. AI, thus, serves as a tool to enhance overall productivity rather than merely replacing human labor.

However, implementing AI into workflows is not an immediate process, and both companies acknowledge the need for comprehensive employee training. Terwilliger highlighted the importance of valuing and rewarding the time employees invest in learning how to use AI systems effectively. Training staff to adapt to AI-driven tasks will require a significant commitment, and organizations must ensure that employees are equipped to utilize the technology to its fullest potential.

Despite the growing integration of AI, Guth reassured that AI is not poised to replace scientists or researchers, particularly in fields like pharmaceuticals. The complexity of biology, such as understanding the evolution of cells, remains beyond the full grasp of AI technology. Guth emphasized that while AI will enhance productivity and speed up processes, the expertise of human scientists will remain essential to making significant breakthroughs in drug development and research.

read more at finance.yahoo.com